Pharmaceutical Major, Lupin's US subsidiary, Lupin Pharmaceuticals Inc. has signed a strategic co-promotion agreement with US based Onset Dermatologics, LLC (Onset) that grants Lupin exclusive rights to promote Onset's Locoid Lotion (hydrocortisone butyrate 0.1%) to Pediatricians in the US. Locoid is the most highly prescribed mid-potency steroid brand in the U.S.Locoid Lotion is a corticosteroid indicated for the topical treatment of mild to moderate Atopic Dermatitis in patients 3 months of age and older. Atopic Dermatitis (AD) is one of the most common skin disorders in young children and has a prevalence of 10% to 20% in the first decade of life.
The addition of Locoid Lotion will enable Lupin to strengthen its US Brand business and expand its product portfolio for the US Pediatrics segment. Lupin's current pediatric portfolio consists of Suprax and Alinia for Oral Suspension and such the Company is well positioned to capitalize on this opportunity. Onset has had minimal promotion of Locoid Lotion to pediatricians. Lupin's 160+ strong specialty sales force will promote Locoid Lotion with Onset providing strategic marketing support thus creating an opportunity for incremental revenues with minimal additional sales or marketing expenses.
No comments:
Post a Comment